,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'destiny breast04', 'breast', 'enhertu']
impressive data for enhertu in destiny breast04 study. 6m os gain in er+ her2 1+/2+
10m os gain in er- her2 1+/2+.
the bar is raised in mbc! 
Breast cancer specialist and professor @DanaFarber Cancer Institute and @HarvardMed. Tweets are my own and not medical advice. COI disclosure: no COI.